Dental implants help maintain bone levels and enable the patient to chew better than conventional restorations. A key threat to the success of treatment is the emergence of implants for specific diseases: peri­implant mucositis and peri­implantitis. Therefore, early diagnosis and treatment are essential to prevent the loss of a dental implant. Research of available literature suggests that in the treatment of peri­implant disease, elimination of bacterial biofilm from the implant surface, whether through surgical or non­surgical approach, should be complemented by an additional therapeutic approach in the form of antibiotic prescribing. Antibiotics in the treatment of peri­implant diseases are used in positive bleeding during probing, with the possible presence of suppuration, the depth of periodontal pockets of 6 mm or more and the presence of loss of alveolar bone. The local application of antibiotics in the area of dental implants is most often aimed at regenerating soft tissue or alveolar bone or fighting inflammation. In order to achieve efficacy and lasting therapeutic effect in the treatment of these pathological conditions, it is necessary to achieve a well­defined concentration of therapeutic pharmacological agents. One of the systems that contain the local antibiotic available on the market is Implacure®, which contains the antibiotics piperacillin and tazobactam. Despite the positive clinical and radiological outcome of the treatment of peri­implantitis with the system mentioned in this case report, further research is needed to clearly define the antibiotic therapeutic regimen and protocols, methodically record the treatment outcomes with at least 3 years of follow­up, and then determine the indications for the use of antibiotics with an assessment of risks and benefits, while at the same time limiting the risk of inappropriate use of antibiotics in order not to further contribute to the development of one of the biggest global problems—antimicrobial resistance.